Macrogenics (MGNX) Receivables - Net (2012 - 2026)
Macrogenics (MGNX) posted quarterly Receivables - Net of $10.4 million for Q1 2026, down 1.12% year-over-year from $10.5 million in Q1 2025, and down 22.04% quarter-over-quarter from $13.4 million in Q4 2025.
Macrogenics (MGNX) Receivables - Net (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has reported Receivables - Net for 15 consecutive years, with $10.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables - Net fell 1.12% year-over-year to $10.4 million; the TTM figure through Mar 2026 stood at $10.4 million (down 1.12% YoY), while the FY2025 annual figure was $13.4 million, up 210.35% from the prior year.
- Receivables - Net declined to $10.4 million in Q1 2026 per MGNX's latest filing, from $13.4 million in the prior quarter.
- Across five years, Receivables - Net topped out at $69.2 million in Q3 2025 and bottomed at $4.3 million in Q4 2024.
- Historically, Receivables - Net has averaged $19.1 million across 5 years, with a median of $12.5 million in 2025.
- Annual changes were most pronounced in 2023 — Receivables - Net plunged 81.56% — and 2025, when it jumped 691.2%.
- Macrogenics' Receivables - Net stood at $56.2 million in 2022, then slumped by 81.56% to $10.4 million in 2023, then tumbled by 58.44% to $4.3 million in 2024, then surged by 210.35% to $13.4 million in 2025, then decreased by 22.04% to $10.4 million in 2026.
- Business Quant data shows MGNX's Receivables - Net at $10.4 million in Q1 2026, $13.4 million in Q4 2025, and $69.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Macrogenics | 268.22 Mn | 201.71 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.43 Mn |
| Mar 31, 2026 | 10.43 Mn |
| Dec 31, 2025 | 13.37 Mn |
| Dec 31, 2025 | 13.37 Mn |
| Sep 30, 2025 | 69.23 Mn |
| Sep 30, 2025 | 69.23 Mn |
| Jun 30, 2025 | 12.53 Mn |
| Jun 30, 2025 | 12.53 Mn |
| Mar 31, 2025 | 10.54 Mn |
| Mar 31, 2025 | 10.54 Mn |
| Dec 31, 2024 | 4.31 Mn |
| Dec 31, 2024 | 4.31 Mn |
| Sep 30, 2024 | 8.75 Mn |
| Sep 30, 2024 | 8.75 Mn |
| Jun 30, 2024 | 6.19 Mn |
| Jun 30, 2024 | 6.19 Mn |
| Mar 31, 2024 | 7.22 Mn |
| Mar 31, 2024 | 7.22 Mn |
| Dec 31, 2023 | 10.37 Mn |
| Dec 31, 2023 | 10.37 Mn |